Effect of a new cholecystokinin antagonist (FK 480) on gene expression of cholecystokinin and secretin in rat intestine
- 15 Downloads
The effects of a new cholecystokinin (CCK) antagonist (FK 480; 0.1 mg/kg per day given by intragastric administration to rats for 3 days) on the expression of the CCK and secretin genes, plasma CCK immunoreactivity, and CCK content in the intestinal mucosa were examined. FK 480 increased the level of CCK mRNA in the intestine to 1.7 times the level in control rats, but did not affect the level of secretin mRNA. It did not increase plasma CCK immunoreactivity or CCK content in the intestinal mucosa. These results suggest that the ingested FK 480 directly increased CCK mRNA level in the intestine and produced a dissociation between the synthesis and release of CCK.
Key wordsCCK antagonist (FK 480) gene expression CCK secretin
Unable to display preview. Download preview PDF.
- 1.Ito H, Sogabe H, Nakarai T, et al. Pharmacological profile of FK 480, a novel cholecystokinin type-A receptor antagonist: Comparison to loxiglumide. J Pharmacol Exp Ther 1994 (in press).Google Scholar
- 2.Tomita H, Miyasaka K, Jimi A, et al. Lack of effect of cholecystokinin receptor antagonist (CR 1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats. Pancreas 1994 (in press).Google Scholar
- 4.Itoh N, Furuya T, Ozaki K, et al. The secretin precursor gene: Structure of the coding region and expression in the brain. J Biol Chem 1991;266:12 595–12 598.Google Scholar